DaVita Inc. is rated Buy with a 12-month price target of $220, implying a 22% upside from current levels around $180. The company's earnings per share growth is mainly fueled by aggressive share buybacks, which enhance per-share value despite flat industry volumes and Medicare rate pressures. Trading at 9.4 times forward earnings, the current valuation makes buybacks more accretive and capital allocation more effective than at previous highs. Key risks include the upcoming Medicare rate decision, high leverage, and earnings volatility, suggesting investors should size positions cautiously.
DaVita (DVA) trades at USD 179.58 on Pluang as of Oct 10, 2026 02:21 WIB, recovering from a 52-week low of USD 103.87 but still below its 52-week high of USD 240.96. The stock's 1-day gain of 1.45% contrasts with its recent 25% drop mentioned in the article. Notably, Pluang investors show strong confidence with 100% buy orders and a typical hold time of 114 days, reflecting steady interest despite volatility.
